Q-omics provides the consensus-scored CICP23 profile across patient tissues and cancer cell-line models. CICP23 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CICP23 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, CICP23 RNA expression shows 8,124 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, LIHC, and TGCT as cancer lineages where CICP23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CICP23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CICP23 survival associations across molecular data types. CICP23 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CICP23 RNA expression–survival associations across cancer types. High CICP23 expression shows unfavorable associations in UCS, MESO, THCA, BRCA and KICH, but favorable associations in BLCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for CICP23 RNA expression.
This table summarizes CICP23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CICP23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CICP23 shows higher tumor expression in LIHC. The LIHC box plot shows higher CICP23 RNA expression in tumor versus normal tissue (log2 FC = +0.009, t-test p = .021).
This table shows molecular features associated with CICP23 in patient tissues and cancer cell lines. In patient samples, CICP23 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
